Baird Financial Group
AVDL

Baird Financial Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Baird Financial Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-37,950
Closed -$818K – 1832
2025
Q4 		$818K Hold
37,950
– – ﹤0.01% 1313
2025
Q3 		$579K Buy
37,950
+7,250
+24% +$94.3K ﹤0.01% 1422
2025
Q2 		$272K Buy
30,700
+20,000
+187% +$176K ﹤0.01% 1619
2025
Q1 		$83.8K Hold
10,700
– – ﹤0.01% 1728
2024
Q4 		$112K Hold
10,700
– – ﹤0.01% 1713
2024
Q3 		$140K Hold
10,700
– – ﹤0.01% 1681
2024
Q2 		$150K Buy
10,700
+700
+7% +$11.4K ﹤0.01% 1701
2024
Q1 		$169K Hold
10,000
– – ﹤0.01% 1691
2023
Q4 		$141K Buy
+10,000
New +$117K ﹤0.01% 1663

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Baird Financial Group's AVDL Position: Q1 2026 in Review

Baird Financial Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 37,950 shares — an estimated $818K sold.

Baird Financial Group first reported a position in AVDL in Q4 2023 and held it in 9 quarters. The position peaked at $818K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Baird Financial Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Baird Financial Group sold 37,950 Avadel Pharmaceuticals shares in Q1 2026, an estimated $818K.
  • Baird Financial Group first reported a position in Avadel Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • Baird Financial Group's Avadel Pharmaceuticals position peaked at $818K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.